You want more than hope.
With YERVOY® (ipilimumab), you have evidence.
46% of patients taking YERVOY alone were alive at year 1.
Estimated percentage, compared with 25% of patients taking an experimental drug alone.
24% of patients taking YERVOY alone were alive at year 2.
Estimated percentage, compared with 14% of patients taking an experimental drug alone.
In a clinical trial, median* overall survival among patients receiving YERVOY was 10 months. Treatment with YERVOY decreased the risk of death by about one third compared to patients who received the experimental drug.
About the YERVOY trial. 676 patients with unresectable or metastatic melanoma participated in a study to measure overall survival. These patients were previously treated with one or more of the following: aldesleukin, dacarbazine, temozolomide, foternustine, or carboplatin. The major goal was to measure how long patients lived with YERVOY in combination with the experimental drug compared to the experimental drug alone.
Patients who received YERVOY alone and patients who took YERVOY plus another experimental drug showed a median overall survival of 10 months. Patients who took the experimental drug alone showed a median overall survival of 6 months.
Select Safety Information: YERVOY can cause serious side effects in many parts of your body which can lead to death. The most common side effects of YERVOY include: tiredness, diarrhea, itching, and rash.
These are not all of the possible side effects of YERVOY. If you have any questions about your health or medicines, talk to your healthcare provider. Please see the Important Safety Information below.
*The median is the middle point at which half of the patients were still alive.